Design and synthesis of a novel ZB716-d6 as a stable isotopically labeled internal standard

ZB716 is a synthetic, steroidal, orally active anti-estrogen agent that is under clinical development for the treatment of estrogen receptor (ER)-positive metastatic breast cancer. The stable isotope-labeled ZB716 was required for use as an internal standard in LC-MS/MS assays. Therefore, a novel deuterated ZB716 (ZB716-d6) as an isotopically labeled internal standard was designed and synthesized through a newly developed route, which prepared ZB716-d6 in eight steps from the commercially available deuterium-labeled starting material [H-2(6)]pentafluoropentanol. This procedure is very practicable and gives the final compound in good yield (19% total yield) and high purity (D, >99%, chemical purity 98%). At present, ZB716-d6 has been successfully used as an internal standard in clinical bioanalysis.

Automated summary

ZB716-d6, a deuterated form of ZB716, was successfully synthesized in eight steps from a commercially available deuterium-labeled starting material and has been utilized as an internal standard in clinical bioanalysis with good yield and high purity.